Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Let’s raise awareness
View:
Post by forhandlaren on Mar 12, 2021 11:52pm

Let’s raise awareness

I've never thought that R+F would give any credit to Sirona Biochem. That is something that the company and it's shareholders must take on.

For years I've advocated in favour of investor events. In Sweden there is regular biotech events streamed on internet where companies presents - is Canada left behind the modern world? I havn't seen Sirona Biochem in this context. If you come across such an event, pass it on the management.

Second, it might be sensitive for the company to reach out to R+F agents and it's customers, but the shareholders are free to act. The R+F agents recieves compensation for sales. The rationale is that they could grow the compensation by investing in a company that delivers key ingredient.

One should also inform that the companies meet on a regular basis and assess other opportunities. I'm sure that anti-wrinkle as a safe compound that would take on Botox head to head is a great carrot.
Comment by lscfa on Mar 13, 2021 1:37am
R+F won't admit that 1067 is the wonder ingredient so then why use it at all? This is the logic Sirona can point out to other derm co.s to make more sales.   
Comment by biorun on Mar 13, 2021 8:08am
All the major players know exactly what Sirona accomplished here with the launch and TFC1067.  Work on that assumption, then focus on this Top 10 company first because they are clearly interested in the clinical results upcoming and also assisted with bringing the trial through to conclusion. As part of this they have some sort of first rights to the data which may give them priority ...more  
Comment by forhandlaren on Mar 13, 2021 10:09am
Not sure if I made myself clear previously. My point is that this company needs additional investors and therefore awareness activities are needed. Carried out by management and marketing firms as well as existing shareholders. Regardless of news, it looks like we recycle the same shareholders over and over again. The news does not reach beyond ourselves! R+F product launch has been announced ...more  
Comment by lscfa on Mar 13, 2021 10:29am
There's plenty of firms for hire to write an investment research report on the co. Fundamental Research, eResearch and Zacks to name a few. Although the reports are paid for by the co. the analysis still needs to be based on facts and assumptions which readers can weight or discount. 
Comment by lscfa on Mar 13, 2021 10:38am
Contact this analyst and ask him to restart coverage.... Original research: Sirona Biochem Corp - by First Berlin Equity Research GmbH First Berlin Equity Research GmbH classified as Sirona Biochem Corp       Company: Sirona Biochem Corp ISIN: CA82967M1005 The reason for the study: Update Recommendation: Buy since: 03/07/2017 Target price: 0.95 ...more  
Comment by MirrorWorldMan on Mar 13, 2021 8:51pm
That Price Target at that time turns out to be accurate, taking into account the dilution. The Market Cap at that time with reduced shares is approximately what it is today with roughly double the outstanding shares. If we did not dilute we would be trading in the .90 range
Comment by biorun on Mar 13, 2021 11:52pm
Jan 31 2017, 165,197,548 shares outstanding 
Comment by PutinKhuylo1 on Mar 14, 2021 1:28pm
The big difference between today and any other point in the past is that the Tuesday/Wednesday commercialization announcement was a definitive confirmation of our science and pipeline. You can't imagine how much better and more confident that makes me feel. IMHO, there are only good things to come.
Comment by Wollikombi on Mar 14, 2021 1:51pm
I agree with them. We will soon have a lot of fun with the share ...
Comment by biorun on Mar 14, 2021 4:30pm
Agree. If something is actually for sale, and people really grab on to it, it brings a different level of credibility to the other work. I am fixated on the CEOs statement "large diversified company". You typically say that when you have a higher degree of confidence in forward developments coming to realization, and those developments, by their financial nature bring you ...more  
Comment by Pandora on Mar 15, 2021 1:49am
An interesting approach from a "raise awareness" perspective: https://heraldsheets.com/vechain-powers-yizhiji-sino-french-cosmetics-brand-to-authenticate-items/
Comment by MirrorWorldMan on Mar 15, 2021 12:18pm
Raising awareness could include those that read this to order their own tube for anyone they know who has skin spots, to validate efficacy and create grass roots support. 
Comment by str8goods4achg on Mar 15, 2021 12:26pm
I will be ordering a tube when it is available. I'll post results too. GTLA
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities